Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business CombinationBusiness Wire • 06/07/22
Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with AlvotechBusiness Wire • 06/03/22
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®Business Wire • 05/24/22
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®Business Wire • 05/16/22
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business CombinationBusiness Wire • 05/11/22
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeBusiness Wire • 04/19/22
Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieBusiness Wire • 04/06/22
FDA Accepts Alvotech's BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®Business Wire • 02/28/22
Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in JapanBusiness Wire • 02/23/22